In the same year, Krueger et al. [81] assessed the risk of malignancies in patients receiving IL-23 inhibitors (risankizumab, guselkumab, and tildrakizumab) compared to those taking TNF inhibitors (adalimumab, infliximab, etanercept, and infliximab and certolizumab pegol), during the first five years of starting the treatment of psoriasis. This evidence concerns the gene IL23A and psoriasis.